Mr. Hugh MacNaught reports

VENTRIPOINT PROVIDES CORPORATE UPDATE AND ANNOUNCES SHAREHOLDER VIDEOCONFERENCE CALL

Ventripoint Diagnostics Ltd. has provided a corporate update and will host a shareholder video conference call.

Dear shareholders,

Ventripoint continues to execute on its strategy to expand commercialization of VMS+, strengthen clinical adoption and position the company for revenue growth.

Key achievements and advances since the last shareholder call

Since the previous shareholder call, the company has continued to make progress in areas including operations, commercialization and clinical engagement, including the following.

Commercialization:

• Closed the sale of one system to a U.S. Midwest children's hospital;
• Increased use of the CRM is resulting in the generation of new qualified leads;
• Engagement with prospective customers through virtual demonstrations.
• Shipment of a system to France for clinical evaluation.

Partnerships and strategic initiatives:

• Relationship with the Ollie Hinkle Heart Foundation expanded to include additional CHD Foundations and Philanthropies such as Jovie's Joy and Ella's Umbrella to support U.S. system placement opportunities;
• Continued collaboration with Lishman Global to support manufacturing and regulatory preparation activities in China to enable market entry;
• Continued evaluation of potential distribution and strategic opportunities in Asia, South America and the Middle East and North Africa region;
• Continued development of strategy and early engagement efforts to expand VMS+ into valvular and structural heart applications;
• Collaboration with Providence Innovation and PHV to secure non-dilutive funding to support placement of systems in the new St. Paul's Hospital;
• Acceptance into UBC's health innovation intelligence program to assist with development of economic models for health system adoption.

Technology, product and regulatory:

• Expanded focus on training, installation and customer support systems;
• Successful completion of manufacturing, quality and regulatory audits.

Corporate development and team expansion:

• Recruitment of Dr. Philip Toleikis to the board of directors;
• Continuing discussions with experienced commercial professionals positioned to transition into roles upon securing financing.

Capital markets and financing:

• Engagement with Red Cloud to provide market-maker services;
• Engagement with More Capital to assist with business development in Canada and the United States;
• Engagement with Growthbridge Ventures for strategic advisory services related to institutional capital.

Shareholder call details

The company will host a shareholder update call to provide additional context on recent developments, commercialization priorities and coming milestones.

Shareholder video conference

Date:  Friday, Oct. 9, 2026

Time:  1 p.m. EST

It will hold a Zoom video conference.

Meeting ID:  824 4505 4768

Passcode:  557461

Dial-in numbers

Dial by your location:

• 1-438-809-7799 Canada;
• 1-587-328-1099 Canada;
• 1-647-558-0588 Canada;
• 1-778-907-2071 Canada;
• 1-780-666-0144 Canada;
• 1-346-248-7799 United States (Houston);
• 1-646-558-8656 United States (New York);
• 1-669-900-9128 United States (San Jose);
• 1-253-215-8782 United States (Tacoma);
• 1-301-715-8592 United States (Washington, D.C.);
• 1-312-626-6799 United States (Chicago).

Meeting ID:  824 4505 4768

Passcode:  557461

Closing comments

Ventripoint is continuing to advance its commercialization strategy toward clinical adoption and growth. The company appreciates the continued support of its shareholders and looks forward to providing further updates during the call.

Sincerely,

Hugh MacNaught,

President and chief executive officer

About Ventripoint Diagnostics Ltd.

Ventripoint is a leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide its future developments. In addition, VMS+ is versatile, and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

We seek Safe Harbor.